8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

___________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

___________________________

CannaPharmaRX, Inc.
(Exact name of registrant as specified in its charter)

___________________________

Delaware	333-251016	27-4635140
(State or other jurisdiction<br><br>of incorporation)	(Commission<br><br>File Number)	(IRS Employer<br><br>Identification No.)

4439 Township Rd 304

Mountain View County, Alberta, Canada T0M 0R0

(Address of principal executive offices, including zip code)

(403) 637-0420

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br><br>Symbol(s)	Name of each exchange<br><br>on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers.

Departure of Director

On January 8, Rick Orman informed the Board of Directors (the “Board”) of CannaPharmaRx, Inc. (the “Company”) of his resignation as a member of the Board effective immediately.

Mr. Orman’s resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company

Item 8.01 Regulation FD Disclosure.

On January 12, 2026, the Company issued a press release providing corporate updates and 2026 growth strategy. A copy of the press release is furnished as Exhibit 99.2 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Resignation letter from Rick Orman
99.2	Press Release dated January 12, 2026
2
---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CANNAPHARMARX, INC.
January 12, 2026	By:	/s/ Constantine Nkafu
	Name:	Constantine Nkafu
	Title:	Chief Executive Officer
3
---

canna_ex991.htm EXHIBIT 99.1

canna_ex992.htm EXHIBIT 99.2

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CannaPharmaRX, Inc. (OTC PINK: CPMD), an emerging leader in global cannabis cultivation and export, is pleased to provide a corporate update outlining recent developments and strategic plans for 2026.

International Export Activities

During the fourth quarter, the Company continued its international export operations with an additional shipment of 250 kg (six batches) to Israel consistently increasing prices as quality increases. Three additional shipments are scheduled for the first quarter of 2026.

Upcoming shipments will include newly developed cannabis strains cultivated over recent months. These strains have demonstrated higher THC concentrations in recent harvests and are in strong demand within the German medical cannabis market.

The new strains include:

Black Candyland, Goat Gas, Caligrape, Lemon Margy, Sour Chillz, and Mac & Cheese.

Plans for 2026

In 2026, the Company plans to continue raising capital to expand its European export capacity. Key initiatives include the construction of four additional cultivation rooms, the development of an additional drying room, and the establishment of a post-harvest processing area compliant with EU-GMP standards. These upgrades will enable CannaPharmaRX to supply its products directly to Germany and additional European markets.

Management believes these strategic investments will position the Company for sustained profitability and long-term operational stability.

Regulatory Update

The cease trade order (the “CTO”) previously issued by the British Columbia Securities Commission (BCSC) was officially revoked, effective December 12, 2025.

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are ‘forward-looking information or statements.’ Forward-looking information or statements can be identified by the use of words such as ‘plans,’ ‘expects,’ or ‘does not expect,’ ‘is expected,’ ‘estimates,’ ‘intends,’ ‘anticipates,’ or ‘does not anticipate,’ or ‘believes,’ or variations of such words and phrases or statements that certain actions, events or results ‘may,’ ‘could,’ ‘would,’ ‘might’ or ‘will’ be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

Contact:

Company: CannapharmaRx

Name: Constantine Nkafu

Website: https://cannapharmarx.com

Phone: 403-637-0420

Mail: info@cannapharmarx.com